ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Early Movers: PRSO, TVGN, ZENA, CCTG, CRDL Stocks to Watch Today!

Early Movers: PRSO, TVGN, ZENA, CCTG, CRDL Stocks to Watch Today!

Today’s pre-market activity highlights significant developments from a range of innovative companies, driving early market attention. Stocks making notable moves include Peraso Inc., Tevogen Bio, ZenaTech, CCSC Technology, and Cardiol Therapeutics, each drawing investor interest with critical announcements and high trading volumes.

Peraso Inc. (NASDAQ: PRSO) announced securing a $1.4 million follow-on order from a South African wireless Internet service provider, further showcasing the demand for its mmWave technology in high-density urban markets. This order follows a previous production shipment earlier in the year and solidifies Peraso’s standing in the wireless connectivity sector.

Tevogen Bio (Nasdaq: TVGN) reported that its artificial intelligence division, Tevogen AI, has joined Microsoft's Startups program, accelerating its drug development initiatives by leveraging Microsoft’s AI capabilities. This partnership marks a key milestone in the company’s mission to expedite drug discovery and reduce costs.

ZenaTech, Inc. (Nasdaq: ZENA) revealed that its subsidiary, ZenaDrone, has acquired a U.S. Design Patent for its second-generation ZenaDrone 1000, significantly enhancing flight times and increasing payload capacity to 80 lbs. This development marks a crucial step forward in ZenaTech’s AI-driven drone technology.

CCSC Technology (NASDAQ: CCTG) saw speculative premarket trading today despite the absence of news, with the company’s diverse portfolio of OEM and ODM interconnect products for industries like automotive, robotics, and telecommunications making it a frequent target for market speculation.

Cardiol Therapeutics (NASDAQ: CRDL) announced plans to advance its CardiolRx™ therapy into the MAVERIC-2 late-stage clinical trial, which will evaluate its effectiveness in treating recurrent pericarditis. The trial is expected to begin in Q4, running alongside the company's upcoming Phase III study across the U.S. and Europe.

As these companies drive innovation in technology, biotechnology, and wireless communication, premarket trading is buzzing with activity. Investors will be closely watching the unfolding developments to gauge their potential market impacts throughout the day.

 

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com


Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.